Research Paper

CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients

Li-Ming Tan1,2,6, Xi Li1,3,4, Cheng-Feng Qiu2, Tao Zhu1,3,4, Cheng-Ping Hu5, Ji-Ye Yin1,3,4, Wei Zhang1,3,4, Hong-Hao Zhou1,3,4, Zhao-Qian Liu1,3,4

1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, P. R. China; 2. Department of Evidence-based Medicine and Clinical Center, The First People’s Hospital of Huaihua City, Huaihua 418000, P. R. China; 3. Institute of Clinical Pharmacology, Central South University, Hunan Key Laboratory of Pharmacogenetics, Changsha 410008, P. R. China; 4. National Clinical Research Center for Geriatric Disorders, Changsha 410008, P. R. China; 5. Department of Respiratory Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P. R. China; 6. Department of Clinical Pharmacy, The Second People’s Hospital of Huaihua City, Huaihua 418000, P. R China.

Corresponding author: Professor Zhao-Qian Liu, Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008; P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China. Tel: +86 731 89753845, Fax: +86 731 82354476, E-mail: zqliu@mail.csu.edu.cn.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.

Received: 2019.06.29; Accepted: 2019.09.30; Published: 2019.10.19

Abstract

Cisplatin-based chemotherapy is the foundation of treatment for major non-small cell lung cancer (NSCLC) patients. However, cisplatin resistance is still a challenging issue, and the molecular mechanisms underlying this resistance remain to be fully explored. CLEC4M, a Ca²⁺-dependent C-type lectin, has recently been found to correlate with tumourigenesis. This study mainly focused on whether CLEC4M impacts clinical prognosis and how CLEC4M contributes to cisplatin resistance in NSCLC. Our results found that CLEC4M was correlated with poor prognosis in patients with lung cancer. In addition, a positive association between CLEC4M expression and the IC50 values of cisplatin was found, which suggests that CLEC4M may impact cisplatin sensitivity. In vitro results from cultured A549 and H1299 cells confirmed that CLEC4M could enhance cisplatin resistance, while CLEC4M knockdown led to higher sensitivity to cisplatin in these cells. Further experiments showed that the underlying mechanisms included inhibition of cisplatin-induced cell apoptosis by CLEC4M and improved DNA repair capacity by upregulating XPA and ERCC1 expression. In addition, CLEC4M was able to promote cell migration with or without cisplatin treatment. Collectively, these findings suggest the potential clinical significance of CLEC4M inhibition in overcoming cisplatin resistance in NSCLC patients.

Key words: CLEC4M, non-small cell lung cancer, cisplatin resistance

Introduction

Lung cancer is the leading cause of cancer-related mortality worldwide (GLOBOCAN project of the World Health Organization in 2012, http://globocan.iarc.fr/). Approximately 85% of lung cancer cases are diagnosed as non-small cell lung cancer (NSCLC)[1]. Platinum-based chemotherapy is the foundation of treatment for most NSCLC patients, including patients with advanced disease, or patients presenting relapse after curative intent surgery[2, 3]. The most commonly used chemotherapy agent is cis-diamine-dichloroplatinum (II), also known as cisplatin, which is used as the backbone of first-line chemotherapy for NSCLC[4]. However, the development of cisplatin resistance remains one of the most challenging problems in the clinical management of patients with NSCLC; cisplatin resistance is a major cause of treatment failure[5]. Accumulating evidence reveals that there are multiple factors involved in cisplatin resistance, including enhanced DNA repair, evasion of apoptosis, drug transport deficiency and reduced drug accumulation[6-8]. Although great advances have
been achieved in this field, the underlying mechanism of cisplatin resistance remains to be fully explored.

Recently, the role of lectins in tumourigenesis has attracted much attention. Selectins (E-, P- and L-selectin) promote lung metastasis by facilitating the formation of the metastatic microenvironment[9]. Liver sinusoidal endothelial cell lectin (LSECtin), an adhesion molecule, is an important player in colorectal carcinoma liver metastasis[10]. CLEC4M, also known as DC-SIGNR, L-SIGN or CD209L, is a Ca2+-dependent C-type lectin. CLEC4M and its homologue DC-SIGN are encoded by the closely related lectin gene cluster on chromosome 19p13.3[11, 12]. Both CLEC4M and DC-SIGN are type-II transmembrane proteins that share very similar genetic structures and protein functional domains. The structure of CLEC4M and DC-SIGN consists of an intra-cellular N-terminal domain, a tandem-repeat neck domain and a C-type lectin carbohydrate recognition domain [11, 12]. Of note, CLEC4M and DC-SIGN are expressed in different tissues; CLEC4M is expressed in the endothelial cells of lung, liver and lymph nodes, while DC-SIGN is expressed in the dendritic cells (DCs)[11]. Both CLEC4M and DC-SIGN have long been considered to perform the same function of recognizing a range of pathogens and mediating the endocytosis of ligands[11, 12], but emerging evidence has demonstrated some differences between their roles in immunity and tumour progression.

As a receptor for viruses (HIV, HCV, SARS-CoV, M. tuberculosis and influenza A viruses)[11, 12], CLEC4M has also been recently identified to associate with tumorigenesis. The level of serum CLEC4M was higher in patients with colon cancer than in healthy controls[13]. Subsequent studies confirmed that CLEC4M could promote colon cancer liver metastasis[14]. Studies in gastric cancer mirrored this finding; the serum CLEC4M level is increased in patients with gastric cancer, especially in patients with liver metastasis, and CLEC4M levels strongly correlate with advanced pathological stage[15]. These findings indicate a novel role for DC-SIGNR in tumour metastasis. In the case of lung cancer, similar results were observed; patients with metastasis had a higher level of serum CLEC4M, while patients without metastasis showed lower serum expression of CLEC4M, compared with healthy controls[16]. Based on these observations, one intriguing issue is whether and how CLEC4M contributes to the aetiology of lung cancer and impacts cisplatin sensitivity. This study mainly focused on the association of CLEC4M with clinical prognosis and the particular role of CLEC4M in cisplatin resistance in lung cancer patients.

**Materials and Methods**

**GDSC Cell lines**

The whole genome expression data and natural log transformed IC50 values of cisplatin for cancer cell lines were obtained from the GDSC database (http://www.cancerrxgene.org/). Based on GDSC release 5.0, a total of 107 lung cancer cell lines were selected to analyse the relationship between CLEC4M expression and cisplatin sensitivity in vitro. Whole-genome mRNA expression information was detected by the Affymetrix Human Genome 133A array. The normalisation method was the Affymetrix Micro Array Suite 5.0 algorithm[17].

**TCGA samples**

TCGA lung squamous cell carcinoma (LUSC) was used to test the relationship between CLEC4M expression and patient prognosis. The TCGA-LUSC datasets contained 504 patients. Based on the clinical information, 119 LUSC patients treated with platinum chemotherapy were screened for subsequent analysis. The whole genome expression data of these datasets were generated by RNA-seq and obtained. The normalized FPKM data and clinical information were downloaded from the NCI genomic data commons (GDC).

**Prognosis analysis in Kmplot**

Kmplot software was used to assess the prognostic value of biomarkers[18]. It incorporates the survival information and transcriptome data (obtained by Affymetrix microarray) from the GEO and TCGA databases. A total of 1926 NSCLC patients (133 from TCGA, 1793 from GEO) were included in Kmplot to analysis the association between CLEC4M expression and the overall survival (OS). Of them, 982 NSCLC patients were included to analysis the association between CLEC4M expression and the first progress time (FP).

**Cell lines and cell culture**

NSCLC cell lines A549 and H1299 were obtained from the American Type Culture Collection (ATCC). Both A549 and H1299 cells were cultured in RPMI-1640 medium supplemented with 10% foetal bovine serum (FBS, Gibco Company) and 1% penicillin/streptomycin (Hyclone). These cells were incubated at 37°C in a humidified atmosphere of 5% CO2.

**Lentiviruses-mediated CLEC4M knockdown or overexpression**

In this study, lentiviruses containing small hairpin RNA (shRNA) specifically targeting human CLEC4M and non-specific shRNA (shControl group), and lentiviruses containing CLEC4M and vector.

---

http://www.jcancer.org
control (vector group) were purchased from Genechem (Shanghai, China). Human CLEC4M shRNA was used to stably silence CLEC4M expression, and lentiviruses containing CLEC4M were used to stably overexpress CLEC4M expression. To silence CLEC4M, 24 h after A549 and H1299 cells were seeded, culture medium mixed with lentiviruses containing CLEC4M shRNA or non-specific shRNA was added into different groups of cells (named shCLEC4M and shControl) for an additional 12 h, and the final multiplicity of infection (MOI) was maintained at 10. Then, supernatants were replaced with normal culture medium, and the cells were continuously cultured for 72 h for subsequent experiments. The transfection process for lentivirus-mediated CLEC4M overexpression is the same as the process of lentivirus-mediated CLEC4M knockdown, which is described in detail above.

Real-time quantitative PCR analysis (RT-qPCR)

Total RNA was extracted from cells using the TRIzol reagent and was reverse transcribed into cDNA with reverse transcription kits according to the manufacturer’s protocols (Thermo Fisher Scientific, Waltham, MA, USA). Real-time quantitative PCR (RT-qPCR) was carried out by SYBR Green Master Mix (Bio-Rad, Hercules, CA) in the CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, CA). The cycle conditions were as follows: 40 cycles, denaturation at 95°C for 5 seconds and amplification at 60°C for 30 seconds. GAPDH was normalized as an internal control. Gene expression was calculated using the 2^-ΔΔCt method.

Western blot analysis

Cells were harvested and lysed in RIPA cell lysis buffer containing 1% PMSF and 1% phosphatase inhibitor. A BCA protein assay kit (Beyotime Institute of Biotechnology) was used to determine the concentration of proteins extracted from the supernatants of the cell lysates.

A total of 25 μg protein in each lane was separated by SDS-PAGE (8–12% gels) and then transferred to PVDF membranes (Millipore, Bedford, MA, USA). After blocking with 5% skimmed milk for 2 h at room temperature, PVDF membranes were incubated with primary antibodies at 4°C overnight. After washing the incubated membranes three times with TBST (0.05% M Tris-base, 0.5 M NaCl supplemented with 0.1% Tween-20), the membranes were incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 2 h at room temperature. After washing the membranes three times with TBST again, blots were visualized with the ECL plus ChemiDoc™ MP Imaging System (Bio-Rad, Hercules, CA, USA). Band intensities were determined using Image Lab software (version 5.1, Bio-Rad). The antibodies used were as follows: β-actin (1:5000; Proteintech), CLEC4M (1:1000; Abcam), Caspase-3 (1:1000; CST), Cleaved Caspase-3 (1:1000; CST), XPA (1:1000; Proteintech), RAD23B (1:1000; Proteintech), XPG (1:1000; Proteintech), and ERCC1 (1:1000; Proteintech).

Cell viability assay

Cells stably transfected with lentiviruses were reseeded in 96-well plates. After attachment, cisplatin in increasing concentrations (0, 20, 40, 60, 80 and 100 μM) was added into each well. Twenty-four hours later, cell counting kit-8 (CCK-8, Beyotime Institute of Biotechnology) was used to determine the cell viability according to the manufacturer’s instructions.

Apoptosis analysis

After stable knockdown or overexpression of CLEC4M, cells were reseeded in 6-well plates and treated with or without cisplatin (50 μM) for 24 h according to the group assignment. Subsequently, these cells were harvested, centrifuged, washed and resuspended in cold-PBS, then incubated with both Annexin V-FITC and propidium iodide (PI) (BD Biosciences) for 15 min at room temperature in the dark. Cell apoptosis rates were analysed by FC. In addition, total cellular protein extractions were used to measure the expression of caspase-3 and cleaved caspase-3 by Western blot analysis.

Transwell assay

Cell migration assays were performed by using Transwell migration chambers (8 μm pore size; Corning, USA). Cell suspensions containing 1% FBS were added to the upper chamber, and the lower chamber was filled with 500 μl of culture medium containing 5% FBS. Twenty-four hours later, non-invading cells in the upper chambers were removed, and the invaded cells in the lower chamber were stained with 0.1% hexamethyl pararosaniline. Representative photos were taken using a TE2000 microscope (Nikon Instruments Inc., Japan) (100×) or SMZ1500 stereomicroscope (Nikon Instruments Inc., Japan) (10×).

Statistical analysis

Means of two continuous normally distributed variables were compared by independent samples Student’s t test. Kruskal-Wallis test or Mann-Whitney U test were used to compare the non-normal continuous variables. Linear regression was used to test the relationship between two quantitative characters. Cox regression was utilized to conduct
survival analysis. The log rank test was used to compare the Kaplan-Meier survival curves. All the analyses were conducted by the SPSS software (version 23.0, IBM Software Inc., New York, NY, USA). The Kaplan-Meier curves and scatter plots were drawn with GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA). To select the best cut-off value, median, tertile and quartile values were used to divide the sample into high expression and low expression groups. A two-tailed \( p \) value < 0.05 was considered statistically significant.

Results

**CLEC4M was negatively associated with prognosis in lung cancer**

In the TCGA-LUSC dataset, after adjusting for age, the expression level of CLEC4M was significantly associated with the OS of patients (cox \( p=0.003 \)). To divide the samples into two groups (CLEC4M high expression group vs. low expression group), the upper quartile (the best cut-off value) was used. We found that subjects with low expression of CLEC4M had longer OS (Log-rank \( p=0.008 \), HR=1.448, 95% CI: 1.086-1.930). Similar results were found in analysing Kmplot NSCLC samples. Patients with higher expression of CLEC4M had shorter OS (Log-rank \( p=0.086 \), HR=1.14, 95% CI: 0.98-1.32) and FP (Log-rank \( p=7.89\times10^{-4} \), HR=1.42, 95% CI: 1.16-1.75) than those with lower CLEC4M expression. The Kaplan-Meier curves of TCGA-LUSC and Kmplot NSCLC samples are shown in Figure 1 A-C.

**Establishment of cell lines with stable knockdown or overexpression of CLEC4M**

CLEC4M was successfully knocked down in the human lung cancer cell lines A549 and H1299 (Figure 2A, 2B, 2E and 2F); we also observed a remarkable increase in CLEC4M expression at both the mRNA and protein levels, which demonstrated that CLECM was successfully overexpressed (Figure 2C, 2D, 2G and 2H). The stable CLEC4M knockdown or overexpression cell lines were used for subsequent experiments.

**Cisplatin resistance-enhancing effect of CLEC4M in lung cancer cells**

To determine whether CLEC4M influences the sensitivity of lung cancer cell lines to cisplatin, we investigated the impact of CLEC4M on cell proliferation. In the GDSC dataset, the expression of CLEC4M was positively correlated with cisplatin IC_{50} values in lung cancer cell lines (\( p=0.009 \); \( r=0.250 \)), as shown in Figure 3 A. The detailed information of the lung cancer cell lines is shown in Table S1. In vitro results also showed that cisplatin treatment in combination with CLEC4M knockdown significantly decreased cell viability when compared with cisplatin treatment alone in both A549 (Figure 3B) and H1299 cells (Figure 3C). As the concentration of cisplatin treatment increased, the IC_{50} values for cisplatin in shCLEC4M/A549 cells were decreased, compared with that in shControl/A549 cells. The same findings were observed in shCLEC4M/H1299 cells. In contrast to the CLEC4M knockdown, we observed that CLEC4M overexpression increased cell viability pronouncedly upon cisplatin treatment in both A549 (Figure 3D) and H1299 cells (Figure 3E). The IC_{50} value for cisplatin was higher in CLEC4M/A549 and CLEC4M/H1299 cells than in vector/A549 and vector/H1299 cells.

**Inhibition of cisplatin-induced cell apoptosis by CLEC4M in lung cancer cells**

The above results showed that CLEC4M enhances cisplatin resistance in lung cancer cells. Next,Annexin V-FITC/PI-stained cells were detected by flow cytometry (FC) to investigate the effect of CLEC4M expression on cell apoptosis induced by cisplatin. As shown in Figure 4A and 4B, cisplatin promoted cell apoptosis across A549 and H1299 cells; CLEC4M knockdown
significantly enhanced cisplatin-induced cell apoptosis in A549 and H1299 cells. In contrast, CLEC4M overexpression attenuated cisplatin-induced cell apoptosis both in A549 and H1299 cells (Figure 4C and 4D). Cleaved caspase-3 is a relevant indicator of cell apoptosis. We found that cisplatin treatment led to a significant increase in cleaved caspase-3 expression, and CLEC4M knockdown further upregulated cisplatin-induced cleaved caspase-3 expression (Figure 4E and 4F), but CLEC4M overexpression reduced cisplatin-induced cleaved caspase-3 expression (Figure 4G and 4H).

Figure 2. Establishment of A549 and H1299 cell lines with stable knockdown or overexpression of CLEC4M. (A-D) CLEC4M expression was measured after lentiviruses containing shCLEC4M and CLEC4M were transfected into the cells (n=3). (E and H) CLEC4M mRNA levels were measured after transfection (n=3). Data are presented as the mean ± SD, **p < 0.01, ***p < 0.001 vs. shCon or Vector.

Figure 3. CLEC4M enhances cisplatin resistance in lung cancer cells. (A) The relationship between CLEC4M expression and the IC50 value for cisplatin was analysed by linear regression after screening of CLEC4M expression data in 107 lung cell lines obtained from the GDSC database. (B-E) Cell viability was determined by CCK-8 (n=4). Cells transfected with lentiviruses containing shCLEC4M (B and C) or containing CLEC4M (D and E) were reseeded in 96-well plates and treated with increasing concentrations (0, 6.25, 12.5, 25, 50 and 100 μM) of cisplatin for 24 h before measurement. Data are presented as the mean ± SD.
Figure 4. CLEC4M inhibits cisplatin-induced cell apoptosis in A549 and H1299 cells. (A-D) Flow cytometry analysis of apoptotic cells by Annexin V-FITC/PI staining (n=4). Cells with CLEC4M knockdown (A and B) or forced expression of CLEC4M (C and D) were reseeded in six-well plates and treated with or without cisplatin (50 μM) for 24 h before measurement. (E-H) Expression of caspase-3 and cleaved caspase-3 in CLEC4M-silenced A549 and H1299 cells (E and F) or CLEC4M-overexpressing A549 and H1299 cells (G and H) treated with or without cisplatin (50 μM) for 24 h. Data are presented as the mean ± SD, *p<0.05, **p<0.01 vs. shCon or vector, ###p<0.01 vs. shCon + cisplatin or vector + cisplatin.
Upregulation of XPA and ERCC1 by CLEC4M

XPG, RAD23B, ERCC1 and XPA are key players in the DNA repair pathway. Our results showed that CLEC4M could regulate ERCC1 and XPA expression in A549 and H1299 cells. CLEC4M knockdown inhibited XPA and ERCC1 mRNA and protein expression (Figure 5A-D). Conversely, overexpression of CLEC4M upregulated the XPA and ERCC1 mRNA levels in these cells, but upregulation of their protein was only observed in H1299 cells (Figure 5E-H).
Migration-promoting effect of CLEC4M in A549 and H1299 cells

In addition, we further detected the effect of CLEC4M on cell migration ability. Consistent with the previous study, we observed that cisplatin (50 μM) decreased the migration of lung cancer cells. Upon cisplatin treatment, A549 and H1299 cells with CLEC4M knockdown showed reduced migration ability when compared with the control groups (Figure 6A and Figure 6B). Conversely, CLEC4M overexpression promoted cell migration and alleviated the inhibitory effect of cisplatin on A549 and H1299 cell migration (Figure 6C and Figure 6D).

Discussion

Cisplatin resistance is a major obstacle for improving the clinical efficacy of treatment for advanced NSCLC patients. This study mainly investigated the biological effect of CLEC4M on cisplatin resistance. Our results showed that CLEC4M was associated with poor patient OS and FP. The positive association between CLEC4M expression and the IC50 values of cisplatin suggests that CLEC4M may impact cisplatin sensitivity. In vitro results from A549 and H1299 cells confirmed that CLEC4M could enhance cisplatin resistance, while CLEC4M knockdown could significantly increase cisplatin sensitivity. Further experiments showed that inhibition of cisplatin-induced cell apoptosis by CLEC4M and improvement in DNA repair capacity by upregulating XPA and ERCC1 expression were among the underlying mechanisms. In addition, we found that
CLEC4M could promote cell migration with or without cisplatin treatment.

The C-type lectin CLEC4M is mainly localized on the endothelial cells of liver, lungs and lymph nodes[11]. CLEC4M was previously identified as a receptor to bind and internalize potential ligands, especially viruses [11]. Recently, the clinical significance of CLEC4M in cancers has been investigated. The high level of CLEC4M in serum may be a potential molecular marker for the diagnosis of early stage colon cancer[13]. The biological effects of CLEC4M in lung cancer remain unclear. In the current study, prognostic analysis of 119 LUSC patients and 1926 NSCLC patients demonstrated that patients with higher expression of CLEC4M showed poorer OS as well as shorter FP. These results indicate that CLEC4M could lead to worse clinical outcomes in lung cancer patients. Cisplatin resistance is a major reason for the negative prognosis of NSCLC patients. Our study verified the initial speculation that CLEC4M promotes cisplatin resistance; A549 and H1299 cell lines with forced CLEC4M expression had greater IC50 values of cisplatin. These findings indicate that the poor clinical outcome of patients with higher CLEC4M expression may result from enhanced cisplatin resistance.

Cisplatin binds to DNA and forms DNA adducts that will induce DNA damage and tumour cell apoptosis [19, 20]. Multiple mechanisms are responsible for cisplatin resistance; one of the most predominant mechanisms is defective apoptosis[6, 21]. It is clear that apoptosis defects not only promote carcinogenesis but also lead to chemoresistance[21]. The results of the current study showed that cisplatin significantly induced apoptosis in both NSCLC cells A549 and H1299, while CLEC4M knockdown further enhanced cisplatin-induced apoptosis. Consistently, CLEC4M overexpression inhibited cisplatin-induced apoptosis. These results indicate that CLEC4M suppresses cisplatin-induced apoptosis and thereby leads to cisplatin resistance in NSCLC cells. Apoptotic signals are regulated at several levels. Caspases are essential regulators in the process of apoptosis[22, 23]. Of these regulators, caspase-3 is recognized as a key player in controlling cellular apoptosis. Upon receiving signals from the upstream activators (caspase-2, -8, -9 and -10), the inactive precursor of caspase-3 is converted into an active form that is responsible for the majority of cellular destruction[24]. Our results showed that CLEC4M suppressed the upregulation of cleaved caspase-3 that was induced by cisplatin in NSCLC cells; when CLEC4M expression is suppressed, the cisplatin-induced upregulation of cleaved caspase-3 was further increased, suggesting that CLEC4M inhibits cisplatin-induced apoptosis in NSCLC cells, which might be the molecular underpinnings of the role of CLEC4M in cisplatin resistance.

The DNA repair capacity (DRC) of tumour cells has a substantial impact on cisplatin sensitivity and/or resistance[25, 26]. Nucleotide excision repair (NER) is considered an important way to sense and respond to cisplatin-induced DNA damage[27]. Four steps are followed to remove DNA lesions by NER: recognition, DNA unwinding, incision by endonucleases, and DNA resynthesize[6, 28]. In the early stage, clinical studies revealed that elevated DRC could enhance cisplatin resistance in NSCLC cell lines[29]. A subsequent study also demonstrated that DRC was an independent predictor of clinical outcomes for NSCLC patients treated with cisplatin-based chemotherapies[30]. The components of NER are a series of protein that display distinct functions in DNA repair. ERCC1 is implicated in DNA incision and has received much attention regarding its role in platinum resistance[28, 31]. XPA protein binds to the damaged site of DNA and provides docking sites for excision. XPA expression is upregulated in cultured NSCLC cell lines resistant to cisplatin resistance[32]. Our results showed that CLEC4M knockdown inhibited ERCC1 and XPA expression in both A549 and H1299 cells. Conversely, CLEC4M over-expression upregulated ERCC1 and XPA expression in H1299 cells. While the mRNA levels of EXCC1 and XPA were also increased in A549 cells, increases at the protein level were not obvious. However, the reason for the different observations between A549 and H1299 cells is not clear. To some extent, current results suggest that DC-SIGNR may enhance DNA repair by increasing EXCC1 and XPA expression. However, we did not detect the direct DNA repair capacity of CLEC4M, and the molecular action also needs to be elucidated.

Finally, we found that CLEC4M promotes the migration of A549 and H1299 cells with or without cisplatin treatment. Knockdown of CLEC4M expression remarkably inhibited the migration of NSCLC cells, which was in line with the observation that CLEC4M promotes the invasion of colon cancer cells. The role of CLEC4M in tumour metastasis has been reported. For example, CLEC4M promotes colon cancer and gastric cancer liver metastasis[13, 14]. In NSCLC patients, the serum levels of CLEC4M were higher in patients with metastasis than in those without metastasis.[16] Collectively, these findings confirmed a role for CLEC4M in NSCLC migration.

Conclusion

In conclusion, to the best of our knowledge, this is the first report to demonstrate that higher...
expression of CLEC4M is associated with poor clinical prognosis in lung cancer patients and enhances the resistance of NSCLC cells to cisplatin. Inhibition of CLEC4M expression significantly increased cisplatin sensitivity, suggesting potential clinical significance for targeting CLEC4M in overcoming cisplatin resistance. However, some limitations exist in this study. The underlying molecular mechanisms and signalling pathways of CLEC4M in the regulation of apoptosis and DNA repair remains to be elucidated.

Supplementary Material
Supplementary table S1.
http://www.jcancer.org/v10p6374s1.pdf

Acknowledgements
This work was supported by the National Key Research and Development Program of China (2016YFC1306900, 2016YFC0905002), National Natural Science Foundation of China (81573508), Hunan Provincial Science and Technology Plan Project (2016JC2066), Natural Science Foundation of Hunan Province in China (2017J3250 and 2018JJ2307), and The Strategy-Oriented Special Project of Central South University in China (ZLXD2017003).

Competing Interests
The authors have declared that no competing interest exists.

References
1. Herbst RS, Mogensztern D, Boshoff C. The biology and management of non-small cell lung cancer. Nature. 2018; 553: 446-54.
2. Fennell DA, Summers Y, Cadranel J, et al. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews. 2016; 44: 42-50.
3. Zheng H, Peng J, Wang W, et al. Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer. J Cancer. 2017; 8: 3856-61.
4. Wang GD, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncology Reports. 2004; 12: 955-65.
5. Tan LM, Qiu CF, Zhu T, et al. Genetic Polymorphisms and Platinum-based Chemotherapy Treatment Outcomes in Patients with Non-Small Cell Lung Cancer: A Genetic Epidemiology Study Based Meta-analysis. Sci Rep. 2017; 7: 5593.
6. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31: 1869-83.
7. Zheng X, Deng Z, Yin J, et al. The association of genetic variations in DNA repair pathways with severe toxicities in NSCLC patients undergoing platinum-based chemotherapy. Int J Cancer. 2017; 141: 236-47.
8. Yin JY, Li X, Zhou HH, et al. Pharmacogenomics of platinum-based chemotherapy sensitivity in NSCLC: toward precision medicine. Pharmacogenomics. 2016; 17: 1365-78.
9. Laubli H, Borsig L. Selectins as mediators of lung metastasis. Cancer Microenviron. 2010; 3: 97-105.
10. Zuo Y, Ren S, Wang M, et al. Novel roles of liver sinusoidal endothelial cell lectin in colon carcinoma cell adhesion, migration and in vivo metastasis to the liver. Gut. 2013; 62: 1169-78.
11. Zhang F, Ren S, Zuo Y. DC-SIGN, DC-SIGNR and LSECtin: C-type lectins for infection. Int Rev Immunol. 2014; 33: 54-66.
12. Khoo US, Chan KY, Chan VS, et al. DC-SIGN and L-SIGN: the SIGNs for infection. J Mol Med (Berl). 2008; 86: 861-74.
13. Jiang Y, Zhang C, Chen K, et al. The clinical significance of DC-SIGN and DC-SIGNR, which are novel markers expressed in human colon cancer. PLoS One. 2016; 9:e114748.
14. Na H, Liu X, Li X, et al. Novel roles of DC-SIGNR in colon cancer cell adhesion, migration, invasion, and liver metastasis. J Hematol Oncol. 2017; 10: 28.
15. Zhang Y, Zhang Q, Zhang M, et al. DC -SIGN by influencing the IncRNA HNRNPJ2 upregulates the expression of CXCR4 in gastric cancer liver metastasis. Mol. Cancer. 2017; 16: 78.
16. Liu X, Zhang H, Su L, et al. Low expression of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein in lung cancer and significant correlations with brain metastasis and natural killer cells. Mol Cell Biochem. 2015; 407: 151-60.
17. Garnett MJ, Edelman RJ, Heidorn SJ, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature. 2012; 483: 503-5.
18. Gyory B, Surowiak P, Bucdzies J, et al. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS One. 2013; 8:e82241.
19. Petrelli F, Coimi A, Cabiddu M, et al. Platinum rechallenge in patients with advanced NSCLC: A pooled analysis. Lung Cancer. 2013; 81: 337-42.
20. Hildebrandt MAT, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opinion on Drug Metabolism & Toxicology. 2009; 5: 745-55.
21. Hassan M, Watari H, AbuAlmaaty A, et al. Apoptosis and Molecular Targeting Therapy in Cancer. Biomed Research International. 2014.
22. Czabotar PE, Lessene G, Strasser A, et al. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014; 15: 49-63.
23. Ola MS, Nawaar M, Alsaen H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 2011; 351: 41-58.
24. Riedl SJ, Shi YG. Molecular mechanisms of caspase regulation during apoptosis. Nature Reviews Molecular Cell Biology. 2004; 5: 897-907.
25. Cruel M, Schellens JH, Beijnen JH, et al. Cisplatin resistance and DNA repair. Cancer treatment reviews. 1997; 23: 341-66.
26. Xiong Y, Huang B1, Yin JY. Pharmacogenomics of platinum-based chemotherapy in non-small cell lung cancer focusing on DNA repair systems. Med Oncol. 2017; 34: 48.
27. Rosell R, Lord RYN, Tanon M, et al. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer. 2002; 38: 217-27.
28. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: The role of DNA repair pathways. Clinical Cancer Research. 2008; 14: 1291-5.
29. Zeng-Rong N, Paterson J, Alpert L, et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res. 1995; 55: 4760-4.
30. Wang LE, Yin M, Dong Q, et al. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. J Clin Oncol. 2011; 29: 4121-8.
31. Olausen KA, Dauant N, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. New England Journal of Medicine. 2006; 355: 983-91.
32. Bowen NA. Nucleotide excision repair: Why is it not used to predict response to platinum-based chemotherapy? Cancer Letters. 2014; 346: 163-71.